1
|
Utomo E, Domínguez-Robles J, Moreno-Castellanos N, Stewart SA, Picco CJ, Anjani QK, Simón JA, Peñuelas I, Donnelly RF, Larrañeta E. Development of intranasal implantable devices for schizophrenia treatment. Int J Pharm 2022; 624:122061. [PMID: 35908633 DOI: 10.1016/j.ijpharm.2022.122061] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 07/19/2022] [Accepted: 07/26/2022] [Indexed: 12/23/2022]
Abstract
In this work the preparation and characterisation of intranasal implants for the delivery of risperidone (RIS) is described. The aim of this work is to develop better therapies to treat chronic conditions affecting the brain such as schizophrenia. This type of systems combines the advantages of intranasal drug delivery with sustained drug release. The resulting implants were prepared using biodegradable materials, including poly(caprolactone) (PCL) and poly(lactic-co-glycolic acid) (PLGA). These polymers were combined with water-soluble compounds, such as poly(ethylene glycol) (PEG) 600, PEG 3000, and Tween® 80 using a solvent-casting method. The resulting implants contained RIS loadings ranging between 25 and 50%. The obtained implants were characterised using a range of techniques including thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), attenuated total reflectance-Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), and Scanning Electron Microscopy (SEM). Moreover, in vitro RIS release was evaluated showing that the addition of water-soluble compounds exhibited significant faster release profiles compared to pristine PCL and PLGA-based implants. Interestingly, PCL-based implants containing 25% of RIS and PLGA-based implants loaded with 50% of RIS showed sustained drug release profiles up to 90 days. The former showed faster release rates over the first 28 days but after this period PLGA implants presented higher release rates. The permeability of RIS released from the implants through a model membrane simulating nasal mucosa was subsequently evaluated showing desirable permeation rate of around 2 mg/day. Finally, following in vitro biocompatibility studies, PCL and PLGA-based implants showed acceptable biocompatibility. These results suggested that the resulting implants displayed potential of providing prolonged drug release for brain-targeting drugs.
Collapse
Affiliation(s)
- Emilia Utomo
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
| | - Juan Domínguez-Robles
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
| | - Natalia Moreno-Castellanos
- CICTA, Department of Basic Sciences, Medicine School, Health Faculty, Universidad Industrial de Santander, Cra 27 calle 9, Bucaramanga 680002, Colombia
| | - Sarah A Stewart
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
| | - Camila J Picco
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
| | - Qonita Kurnia Anjani
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK; Fakultas Farmasi, Universitas Megarezky, Jl. Antang Raya, No. 43, Makassar 90234, Indonesia
| | - Jon Ander Simón
- Radiopharmacy Unit, Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, IdiSNA, 31008 Pamplona, Spain
| | - Iván Peñuelas
- Radiopharmacy Unit, Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, IdiSNA, 31008 Pamplona, Spain
| | - Ryan F Donnelly
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
| | - Eneko Larrañeta
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK.
| |
Collapse
|
2
|
Visan AI, Ristoscu C, Popescu-Pelin G, Sopronyi M, Matei CE, Socol G, Chifiriuc MC, Bleotu C, Grossin D, Brouillet F, Grill SL, Bertrand G, Zgura I, Cristescu R, Mihailescu IN. Composite Drug Delivery System Based on Amorphous Calcium Phosphate-Chitosan: An Efficient Antimicrobial Platform for Extended Release of Tetracycline. Pharmaceutics 2021; 13:pharmaceutics13101659. [PMID: 34683952 PMCID: PMC8537227 DOI: 10.3390/pharmaceutics13101659] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Revised: 10/04/2021] [Accepted: 10/04/2021] [Indexed: 11/26/2022] Open
Abstract
One major warning emerging during the first worldwide combat against healthcare-associated infections concerns the key role of the surface in the storage and transfer of the virus. Our study is based on the laser coating of surfaces with an inorganic/organic composite mixture of amorphous calcium phosphate–chitosan–tetracycline that is able to fight against infectious agents, but also capable of preserving its activity for a prolonged time, up to several days. The extended release in simulated fluids of the composite mixture containing the drug (tetracycline) was demonstrated by mass loss and UV–VIS investigations. The drug release profile from our composite coatings proceeds via two stages: an initial burst release (during the first hours), followed by a slower evolution active for the next 72 h, and probably more. Optimized coatings strongly inhibit the growth of tested bacteria (Enterococcus faecalis and Escherichia coli), while the drug incorporation has no impact on the in vitro composite’s cytotoxicity, the coatings proving an excellent biocompatibility sustaining the normal development of MG63 bone-like cells. One may, therefore, consider that the proposed coatings’ composition can open the prospective of a new generation of antimicrobial coatings for implants, but also for nosocomial and other large area contamination prevention.
Collapse
Affiliation(s)
- Anita Ioana Visan
- National Institute for Laser, Plasma and Radiation Physics, 077125 Magurele, Romania; (C.R.); (G.P.-P.); (M.S.); (C.E.M.); (G.S.); (R.C.)
- Correspondence: (A.I.V.); (I.N.M.); Tel.: +40-21-457-44-91 (I.N.M.)
| | - Carmen Ristoscu
- National Institute for Laser, Plasma and Radiation Physics, 077125 Magurele, Romania; (C.R.); (G.P.-P.); (M.S.); (C.E.M.); (G.S.); (R.C.)
| | - Gianina Popescu-Pelin
- National Institute for Laser, Plasma and Radiation Physics, 077125 Magurele, Romania; (C.R.); (G.P.-P.); (M.S.); (C.E.M.); (G.S.); (R.C.)
| | - Mihai Sopronyi
- National Institute for Laser, Plasma and Radiation Physics, 077125 Magurele, Romania; (C.R.); (G.P.-P.); (M.S.); (C.E.M.); (G.S.); (R.C.)
| | - Consuela Elena Matei
- National Institute for Laser, Plasma and Radiation Physics, 077125 Magurele, Romania; (C.R.); (G.P.-P.); (M.S.); (C.E.M.); (G.S.); (R.C.)
| | - Gabriel Socol
- National Institute for Laser, Plasma and Radiation Physics, 077125 Magurele, Romania; (C.R.); (G.P.-P.); (M.S.); (C.E.M.); (G.S.); (R.C.)
| | - Mariana Carmen Chifiriuc
- Department of Microbiology, Faculty of Biology, University of Bucharest, 060101 Bucharest, Romania;
- Earth, Environmental and Life Sciences Division, Research Institute of the University of Bucharest, 050567 Bucharest, Romania;
| | - Coralia Bleotu
- Earth, Environmental and Life Sciences Division, Research Institute of the University of Bucharest, 050567 Bucharest, Romania;
- Stefan S. Nicolau Institute of Virology, 285 Mihai Bravu Ave, Sect. 3, PO 77, P.O. Box 201, Bucharest 030304, Romania
| | - David Grossin
- CIRIMAT, CNRS, INP-ENSIACET, Université de Toulouse, 4 allée Emile Monso, 31030 Toulouse, France; (D.G.); (G.B.)
| | - Fabien Brouillet
- CIRIMAT, CNRS, Université Toulouse 3-Paul Sabatier, 35 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (F.B.); (S.L.G.)
| | - Sylvain Le Grill
- CIRIMAT, CNRS, Université Toulouse 3-Paul Sabatier, 35 Chemin des Maraîchers, CEDEX 9, 31062 Toulouse, France; (F.B.); (S.L.G.)
| | - Ghislaine Bertrand
- CIRIMAT, CNRS, INP-ENSIACET, Université de Toulouse, 4 allée Emile Monso, 31030 Toulouse, France; (D.G.); (G.B.)
| | - Irina Zgura
- National Institute of Materials Physics, 077125 Magurele, Romania;
| | - Rodica Cristescu
- National Institute for Laser, Plasma and Radiation Physics, 077125 Magurele, Romania; (C.R.); (G.P.-P.); (M.S.); (C.E.M.); (G.S.); (R.C.)
| | - Ion N. Mihailescu
- National Institute for Laser, Plasma and Radiation Physics, 077125 Magurele, Romania; (C.R.); (G.P.-P.); (M.S.); (C.E.M.); (G.S.); (R.C.)
- Correspondence: (A.I.V.); (I.N.M.); Tel.: +40-21-457-44-91 (I.N.M.)
| |
Collapse
|
3
|
Raguraman V, Suthindhiran K. Preparation and characterisation of magnetosomes based drug conjugates for cancer therapy. IET Nanobiotechnol 2020; 14:815-822. [PMID: 33399113 PMCID: PMC8676143 DOI: 10.1049/iet-nbt.2020.0082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 06/23/2020] [Accepted: 07/28/2020] [Indexed: 11/19/2022] Open
Abstract
The authors report a novel, effective and enhanced method of conjugating anticancer drug, paclitaxel and gallic acid with magnetosomes. Here, anticancer drugs were functionalised with magnetosomes membrane by direct and indirect (via crosslinkers: glutaraldehyde and 3-aminopropyltriethoxysilane) adsorption methods. The prepared magnetosome-drug conjugates were characterised by Fourier transform infrared, zeta potential, field-emission scanning electron microscope and thermogravimetric analysis/differential scanning calorimetry. The drug-loading efficiency and capacity were found to be 87.874% for paclitaxel (MP) and 71.3% for gallic acid (MG), respectively as calculated by ultraviolet spectroscopy and high-performance liquid chromatography. The drug release demonstrated by the diffusion method in phosphate buffer (PBS), showing a prolonged drug release for MP and MG, respectively. The cytotoxicity effect of the MP and MG displayed cytotoxicity of 69.71%, 55.194% against HeLa and MCF-7 cell lines, respectively. The reactive oxygen species, acridine orange and ethidium bromide and 4, 6-diamidino-2-phenylindole staining of the drug conjugates revealed the apoptotic effect of MP and MG. Further, the regulation of tumour suppressor protein, p53 was determined by western blotting which showed an upregulation of p53. Comparatively, the magnetosome-drug conjugates prepared by direct adsorption achieved the best effects on the drug-loading efficiency and the increased percentage of cancer cell mortality and the upregulation of P53. The proposed research ascertains that magnetosomes could be used as effective nanocarriers in cancer therapy.
Collapse
Affiliation(s)
- Varalakshmi Raguraman
- Marine Biotechnology and Bioproducts Laboratory, School of Biosciences and Technology, Vellore Institute of Technology, Vellore-632014, Tamilnadu, India
| | - Krishnamurthy Suthindhiran
- Marine Biotechnology and Bioproducts Laboratory, School of Biosciences and Technology, Vellore Institute of Technology, Vellore-632014, Tamilnadu, India.
| |
Collapse
|
4
|
Naiserová M, Kubová K, Vysloužil J, Bernatoniene J, Brokalakis I, Vetchý D. (Meth)acrylate copolymers of Eudragit® type in oral tablet technology. Ceska Slov Farm 2019; 68:183-197. [PMID: 31896262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
This review focuses on the characterization of (meth)acrylate copolymers - Eudragit®, describing their thermal treatment behaviour, possible interactions between cationic and anionic polymers, incompatibilities related to Eudragits® and their use in the pharmaceutical technology of oral tablets. In summary, Eudragit® copolymers are divided into soluble ones, insoluble ones and a combination of these two types. The combination of soluble and insoluble poly(meth)acrylate gave a new type of polymer, Eudragit® FL. In oral tablet technology, Eudragits® are widely used in matrix tablets, either alone or in combination, where they mainly provide sustained drug release. To a lesser extent, Eudragits® are used in gastroretentive systems. Moreover, Eudragits® are also of great importance in coated tablets technology, where these enteric polymers provide specific drug targeting to certain parts of the digestive tract, mainly to the small intestine or colon. Important systems such as CODESTM and MMX® technology are mentioned. Last but not least an overview table of currently available oral medicinal products on the Czech market, where at least one of the Eudragits® was used as a film-forming agent, is included.
Collapse
|
5
|
Speer I, Preis M, Breitkreutz J. Novel Dissolution Method for Oral Film Preparations with Modified Release Properties. AAPS PharmSciTech 2018; 20:7. [PMID: 30560468 DOI: 10.1208/s12249-018-1255-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Accepted: 11/21/2018] [Indexed: 11/30/2022] Open
Abstract
Oromucosal film preparations have gained popularity in pharmaceutical research and development. Therefore, oral films have been integrated into the monograph "oromucosal preparations" of the European Pharmacopeia in 2012. Regulatory authorities explicitly demand dissolution studies for films, but neither refer to suitable methods nor established specifications. Test methods described in the literature are often limited to immediate release formulations or not applicable to investigate the drug release of films with prolonged release profiles considering the different stages of gastrointestinal transit. The aims of this study were to develop a dissolution test method, which is suitable to investigate the drug release of film preparations with immediate as well as modified release profiles and to explore the potential of the test setup considering some physiological characteristics. Therefore, a conventional flow-through cell was equipped with in-house built sample holders. Three-dimensional printing technology was used for prototyping one of the sample holders. Four different types of films were investigated, such as ODFs with immediate (ODFIR) and prolonged release (ODFPR) characteristics as well as a double-layer film (ODFDL), produced with a water-insoluble shielding layer. Anhydrous theophylline was used as a model drug for all film types. Introducing special fixtures for oral films to a conventional flow-through cell enables successful determination of the drug release behavior of oral film preparations with immediate as well as modified release properties. Investigating ODFDL, the application of film sample holders with backing plates such as film sample holder with backing plate (FHB) and 3D printed film sample holder (FH3D) showed prolonged release profiles with 14.6 ± 1.30% theophylline dissolved within 2 h for FHB compared to 92.9 ± 3.33% for the film sample holder without backing plate (FH). This indicates their suitability to examine the integrity of the shielding layer. The application of the backing plate further decreased the drug release of ODFPR < 315 to 61.0 ± 1.69% dissolved theophylline within 2 h using FHB compared to 82.3 ± 0.74% using FH, due to a reduced ODF surface exposed to the dissolution medium. The potential of the dissolution test setup to consider physiological conditions of the human gastrointestinal transit was investigated by applying different flow rates and media compositions to simulate conditions within the oral cavity, stomach, and intestine. For the application of a low flow rate of 1 ml/min, comparable to the salivary flow within the oral cavity, decreased theophylline release was observed, while similar release profiles were obtained for flow rates between 2 and 8 ml/min. Substantial impact on the theophylline release was exerted by varying the composition of the dissolution medium. Since the drug release from ODFPR is controlled by diffusion through a water-insoluble matrix, ion species and concentration strongly affect the release behavior. In the future, IVIVC studies have to be performed to explore, whether obtained data can be used to predict drug release behavior of ODFs during the human gastrointestinal transit.
Collapse
|
6
|
Szekalska M, Sosnowska K, Czajkowska-Kośnik A, Winnicka K. Calcium Chloride Modified Alginate Microparticles Formulated by the Spray Drying Process: A Strategy to Prolong the Release of Freely Soluble Drugs. Materials (Basel) 2018; 11:E1522. [PMID: 30149531 PMCID: PMC6163791 DOI: 10.3390/ma11091522] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Revised: 08/20/2018] [Accepted: 08/21/2018] [Indexed: 11/16/2022]
Abstract
Alginate (ALG) cross-linking by CaCl₂ is a promising strategy to obtain modified-release drug delivery systems with mucoadhesive properties. However, current technologies to produce CaCl₂ cross-linked alginate microparticles possess major disadvantages, such as a poor encapsulation efficiency of water-soluble drugs and a difficulty in controlling the process. Hence, this study presents a novel method that streamlines microparticle production by spray drying; a rapid, continuous, reproducible, and scalable technique enabling obtainment of a product with low moisture content, high drug loading, and a high production yield. To model a freely water-soluble drug, metformin hydrochloride (MF) was selected. It was observed that MF was successfully encapsulated in alginate microparticles cross-linked by CaCl₂ using a one-step drying process. Modification of ALG provided drug release prolongation-particles obtained from 2% ALG cross-linked by 0.1% CaCl₂ with a prolonged MF rate of dissolution of up to 12 h. Cross-linking of the ALG microparticles structure by CaCl₂ decreased the swelling ratio and improved the mucoadhesive properties which were evaluated using porcine stomach mucosa.
Collapse
Affiliation(s)
- Marta Szekalska
- Department of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, 15222 Białystok, Poland.
| | - Katarzyna Sosnowska
- Department of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, 15222 Białystok, Poland.
| | - Anna Czajkowska-Kośnik
- Department of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, 15222 Białystok, Poland.
| | - Katarzyna Winnicka
- Department of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, 15222 Białystok, Poland.
| |
Collapse
|
7
|
Liang C, Wen J, Liao X. A visible-light-controlled platform for prolonged drug release based on Ag-doped TiO 2 nanotubes with a hydrophobic layer. Beilstein J Nanotechnol 2018; 9:1793-1801. [PMID: 29977712 PMCID: PMC6009292 DOI: 10.3762/bjnano.9.170] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Accepted: 05/24/2018] [Indexed: 05/28/2023]
Abstract
In this work, a visible-light-controlled drug release platform was constructed for localized and prolonged drug release based on two-layer titania nanotubes (TNTs) fabricated using by an in situ voltage up-anodization process. The visible-light photocatalytic activity is improved by loading Ag onto the TNTs by NaBH4 reduction. Then, the TNTs containing Ag nanoparticles were modified with dodecanethiol (NDM) to create a hydrophobic layer. To demonstrate the visible-light-controlled drug release, the Zn2+ release behavior of the samples was investigated. In the initial 12 h, TNTs without NDM displayed a faster release rate with 29.4% Zn2+ release, which was more than three times that of the TNTs with NDM (8.7% Zn2+ release). Upon visible-light illumination, drug release from the sample coated with NDM was shown to increase due to the photocatalytic decomposition of NDM. The amount of released Zn2+ for this sample increased up to 71.9% within 12 h, indicating visible-light-controlled drug release. This drug release system may exhibit promising application as a localized, prolonged drug delivery platform.
Collapse
Affiliation(s)
- Caihong Liang
- College of Materials Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China
| | - Jiang Wen
- College of Materials Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China
| | - Xiaoming Liao
- College of Materials Science and Engineering, Sichuan University, Chengdu, Sichuan 610065, China
| |
Collapse
|
8
|
Liu D, Jiang T, Cai W, Chen J, Zhang H, Hietala S, Santos HA, Yin G, Fan J. An In Situ Gelling Drug Delivery System for Improved Recovery after Spinal Cord Injury. Adv Healthc Mater 2016; 5:1513-21. [PMID: 27113454 DOI: 10.1002/adhm.201600055] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Revised: 03/02/2016] [Indexed: 12/11/2022]
Abstract
Therapeutic strategies for the spinal cord injury (SCI) are limited by the current available drug delivery techniques. Here, an in situ gelling drug delivery system (DDS), composed of a Poloxamer-407, a 188 mixture-based thermoresponsive hydrogel matrix and, an incorporated therapeutic compound (monosialoganglioside, GM1), is developed for SCI therapy. A low-thoracic hemisection in rats is used as SCI model to evaluate therapeutic efficiency. The GM1-incorporating Poloxamer-407 and 188 polymer solution is converted to a hydrogel (GM1-hydrogel) upon instillation to the injured spinal cord, due to the increased temperature. At body temperature, the thermoresponsive hydrogel prolongs the release of GM1 for about 1 month, due to the superposition of dissolution and swelling (anomalous transport) of the hydrogel matrix. The sustained release of the GM1-hydrogel enables the prolonged residence time of GM1 at the injured spinal cord, decreases the frequency of administration and, consequently, may improve patient compliance. After SCI, the administration of GM1-hydrogel to the lesion site inhibits the apoptotic cell death and glial scar formation, enhances the neuron regeneration, provides neuroprotection to the injured spinal cord, and improves the locomotor recovery. Overall, this study opens future perspectives for the treatment of SCI with a prolonged drug release DDS.
Collapse
Affiliation(s)
- Dongfei Liu
- Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki FI‐00014 Helsinki Finland
| | - Tao Jiang
- Department of Orthopaedics The First Affiliated Hospital of Nanjing Medical University Jiangsu 210029 China
| | - Weihua Cai
- Department of Orthopaedics The First Affiliated Hospital of Nanjing Medical University Jiangsu 210029 China
| | - Jian Chen
- Department of Orthopaedics The First Affiliated Hospital of Nanjing Medical University Jiangsu 210029 China
| | - Hongbo Zhang
- Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki FI‐00014 Helsinki Finland
| | - Sami Hietala
- Laboratory of Polymer Chemistry Department of Chemistry University of Helsinki FI‐00014 Helsinki Finland
| | - Hélder A. Santos
- Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki FI‐00014 Helsinki Finland
| | - Guoyong Yin
- Department of Orthopaedics The First Affiliated Hospital of Nanjing Medical University Jiangsu 210029 China
| | - Jin Fan
- Department of Orthopaedics The First Affiliated Hospital of Nanjing Medical University Jiangsu 210029 China
| |
Collapse
|